MiMedx Group, Inc.
MDXGHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company carries a $681.5M market cap, placing it firmly in the small-cap category. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Market Cap
$681.5M
Beta
1.42
P/E (TTM)
116.75
P/E (Fwd)
23.35
EPS (TTM)
$0.04
EPS (Fwd)
$0.20
ROE
2.9%
ROA
1.9%
Cash
$135.8M
Total Debt
$17.2M
Free CF
$41.4M
52W Change
-33.7%
Annual Financials
Cash vs Debt
Where MDXG stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, MDXG finished 8.17% above its 150-day moving average ($4.16) and 5.86% below its 200-day moving average ($4.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDXG overbought or oversold?
At the August 31, 2026 close, MDXG's RSI(14) was 60.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $135.8M in cash and $17.2M in debt, MDXG maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $41.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 2.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $267.8M (2022) to $418.6M (2025), reflecting a 56% increase over the period.
With cash comfortably exceeding debt, MDXG has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MiMedx Group, Inc.'s trajectory.